Can you cure lung cancer by removing both lungs and putting in new ones?
In carefully chosen patients, it looks like you can come close. In this study, a lung transplant for advanced lung cancer produced 100 percent survival at one year, compared with 40.8 percent for patients who stayed on standard treatment.
That is a startling gap, and it comes from a group of people who had run out of options. All of them had stage IV non-small cell lung cancer that no longer responded to treatment. The one unusual thing about them was where the cancer sat. It had spread through both lungs, but it had not traveled anywhere else in the body. No liver, no bones, no brain. For most of these patients, the thing that was going to kill them was not cancer spreading. It was their lungs failing.
That raises an old and slightly radical idea. If the disease is trapped inside one organ, and that organ can be replaced, what happens if you simply take the organ out?
What the data show
Doctors at Northwestern Medicine built a registry called DREAM and followed 98 adults in exactly this situation. Seventeen of them received a double lung transplant, meaning both lungs were removed and replaced. The other 81 continued with standard medical care, which usually means chemotherapy, immune therapy, or targeted drugs.
The survival difference was large. Using Kaplan-Meier estimates, which is a standard way of tracking survival over time, one-year overall survival was 100 percent in the transplant group and 40.8 percent in the group that stayed on medical management. In other words, roughly six of every ten patients on standard care had died within a year, while every transplant patient was still alive.
The transplant patients also did about as well as people who get lung transplants for reasons that have nothing to do with cancer. The same team compared them to 306 patients transplanted for end-stage lung disease, and the cancer group held up. That matters, because it suggests these patients were not unusually fragile and were not being ruined by the surgery itself.
Cancer did come back in 4 of the 17 transplant patients over extended follow-up that ran through January 2026. Two patients in the transplant group died, and neither death was caused by cancer.
Dr. Kumar’s Take
I read this and my first reaction was surprise, my second was caution, and both are still true.
The surprise is easy to explain. Stage IV lung cancer that has stopped responding to treatment is, in most conversations I have had, a terminal diagnosis measured in months. A 100 percent one-year survival number in that setting is not something I expected to see in my career. And the recurrence pattern is telling. Only 4 of 17 had the cancer return, and the deaths that did happen were not from cancer at all. That fits the theory the researchers are testing: if the disease truly lives only in the lungs, taking out the lungs takes out the disease.
The caution is just as important. Seventeen patients is a small number. These were not average lung cancer patients, they were the rare few whose cancer stayed put, and someone made a careful judgment call about each one. The comparison group was not randomly assigned, so the people who got transplants may have been healthier or luckier in ways that are hard to measure. And a transplant is not a light thing. It means a lifetime of drugs that hold your immune system down, which is a strange bargain when the disease you are treating is cancer.
So I would call this a real signal, not a settled answer. It is the kind of result that should open a door, carefully, rather than swing it wide.
Who this actually applies to
Almost nobody with lung cancer will be a candidate for this, and it is worth being blunt about that. The whole approach depends on one narrow condition: the cancer must be confined to the lungs and nowhere else. Once tumor cells have set up shop in the bones or the brain or the liver, removing the lungs removes only part of the problem, and the rest keeps growing.
Patients also have to be well enough to survive a major operation and to tolerate the anti-rejection medications afterward. That combination, sick enough to need new lungs but strong enough to receive them, with cancer that has politely stayed in one place, describes a very small group of people.
How confident should we be?
This was a registry study, not a randomized trial. The researchers watched what happened to patients rather than flipping a coin to decide who got a transplant. That design cannot fully separate the effect of the transplant from the effect of being the kind of patient who gets offered one.
The follow-up is also still young for a cancer question. Four recurrences in 17 patients tells us the disease can find its way back, and we do not yet know what the numbers look like at five or ten years. What the study does establish is that the operation is survivable in this population and that the early results are far better than doing nothing new. Confirming it will take more centers, more patients, and more time.
Practical Takeaways
- If you or a family member has stage IV non-small cell lung cancer, ask the oncology team whether imaging shows the disease is confined to the lungs, because that single fact is what makes this option even thinkable.
- Treat this as an option to discuss at a major transplant center, not something a general oncology clinic can arrange, since only a handful of programs are doing it and selection is strict.
- Understand the trade before hoping for it, as a lung transplant means lifelong immune-suppressing drugs, frequent monitoring, and real surgical risk.
- Do not read this as a reason to delay or skip standard treatment, because transplant was only considered here after other therapies had already failed.
Related Studies and Research
- A daily pill nearly doubled survival in advanced pancreatic cancer
- New mRNA flu vaccine works better than standard flu shots in older adults
- A plant-based diet lowered heart disease risk over 20 years
- The discovery of penicillin: new insights after 75+ years
FAQs
Why was lung transplant for cancer considered off-limits for so long?
The fear was that anti-rejection drugs would let any leftover cancer explode. Those drugs work by holding the immune system back so the body does not attack the new organ, and a suppressed immune system is theoretically worse at policing tumor cells. Transplant programs also worried about giving a scarce donor organ to someone likely to relapse quickly, since there are never enough lungs for everyone on the waiting list. This study does not erase those concerns, but it does show that in a tightly selected group, the feared disaster did not happen in the first year.
Does the cancer ever come back after the new lungs are in?
Yes. In this registry, cancer returned in 4 of the 17 transplant patients during follow-up that continued through January 2026. That is roughly one in four, which is a real number and not a footnote. It suggests some tumor cells can survive elsewhere in the body even when scans say the disease is lung-limited. What stands out is that the two deaths in the transplant group were not caused by cancer, so recurrence did not automatically mean a rapid decline.
How is this different from surgery that removes part of a lung?
Standard lung cancer surgery takes out a tumor and some surrounding tissue, and it is normally reserved for earlier-stage disease where the cancer sits in one spot. The patients in this study had cancer scattered through both lungs, which puts ordinary surgery off the table entirely because there would be no healthy lung left. A double lung transplant sidesteps that by removing all of the diseased tissue and supplying new lungs to breathe with. The trade is that you exchange a cancer problem for a transplant problem, including a lifetime of medication.
Bottom Line
In a small Northwestern registry of patients with treatment-refractory stage IV lung cancer that had stayed inside the lungs, a double lung transplant was followed by 100 percent one-year survival, compared with 40.8 percent for those who continued standard care. Cancer came back in 4 of 17 transplant patients, and the 2 deaths in that group had nothing to do with cancer. This is 17 people, not a randomized trial, so it is not proof. But it supports a simple and powerful idea: when a cancer stays inside one organ, replacing that organ may take the cancer with it.
